Clinical trials · Washington, D.C., DC
Lung Cancer (NSCLC) clinical trials in Washington, D.C.
We’re tracking 157 recruiting lung cancer (nsclc) studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06868485RecruitingPhase 2
Study of WSD0922-FU for advanced lung cancer with C797S mutation
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Fairfax, VirginiaAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Fairfax, VirginiaAges 18 years+ - NCT07094204RecruitingPhase 1
Study of ASP5834 for advanced solid tumors with KRAS changes
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
Fairfax, VirginiaAges 18 years+ - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
Fairfax, VirginiaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Fairfax, VirginiaAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Fairfax, VirginiaAges 18–99 - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Fairfax, VirginiaAges 18 years+ - NCT07554339RecruitingPhase 3
Calderasib and Durvalumab for Advanced Lung Cancer After Chemotherapy
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
Fairfax, VirginiaAges 18 years+ - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Fairfax, VirginiaAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Columbia, MarylandAges 18 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Glen Burnie, MarylandAges 18 years+ - NCT06800339RecruitingPhase 1
Immunotherapy and radiation before surgery for lung cancer
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Glen Burnie, MarylandAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Annapolis, MarylandAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Annapolis, MarylandAges 18 years+ - NCT04945317Enrolling by invitation
ROSE to improve lung cancer marker testing with a breathing scope
This trial studies a quick scan method (called ROSE) during bronchoscopy to help doctors get the right lung cancer tissue and test cancer markers more accurately. If you are being evaluated for non-small cell lung cancer, the study may improve how well and how fast your samples can be tested.
Baltimore, MarylandAges 18 years+ - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Baltimore, MarylandAges 18 years+ - NCT02984761Recruiting
Surgery vs focused radiation for early lung cancer
This trial compares two ways to treat early-stage lung cancer: surgery or a precise type of radiation called stereotactic radiotherapy. It aims to find out which approach works best for people whose cancer is small and has not spread.
Baltimore, MarylandAges 18 years+ - NCT05168566RecruitingPhase 2
Sutetinib for lung cancer with a specific EGFR change
This Phase 2 study tests sutetinib capsules in people with advanced (locally advanced or metastatic) non-small cell lung cancer. It’s for tumors that have a specific, uncommon EGFR mutation, and aims to see how well the drug can control the cancer with limited prior chemotherapy.
Baltimore, MarylandAges 18 years+ - NCT06780085RecruitingPhase 2
Study of new drugs for advanced lung cancer
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
Baltimore, MarylandAges 18 years+ - NCT05317858RecruitingPhase 3
Open the brain’s blood barrier to treat lung cancer brain spots
This trial tests whether using focused ultrasound to temporarily open the brain’s blood barrier—plus standard immune therapy—can better treat non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to help medicines reach the brain tumor spots more effectively, while still using the usual lung cancer treatment.
Baltimore, MarylandAges 18–100 - NCT06996782RecruitingPhase 1/Phase 2
Lung cancer study testing new combination treatments
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Baltimore, MarylandAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Lung Cancer (NSCLC) trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting lung cancer (nsclc) studies listed above.
- NEXT Oncology · 4 studies
- Johns Hopkins University · 3 studies
- NEXT Virginia · 2 studies
- Virginia Cancer Specialists · 2 studies
- Advanced Molecular Imaging and Therapy
- Baltimore VA Medical Center
- Baltimore Washington Medical Center- Tate Cancer Center
- Greater Baltimore Medical Center
What taking part in a lung cancer (nsclc) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there lung cancer (nsclc) clinical trials near Washington, D.C.?
- Yes. We're currently tracking 157 recruiting lung cancer (nsclc) studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer (nsclc) study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer (nsclc) studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.